Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 13/20 | 0.62 |
| ▸ | MMP13 | P45452 | 12/20 | 0.62 |
| ▸ | MMP1 | P03956 | 11/20 | 0.62 |
| ▸ | ADAM17 | P78536 | 8/20 | 0.52 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.39 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7005730 | 0.93 | MMP9 (0.64) | MMP9MMP13MMP1ADAM17NUDT14 | |
| SCHEMBL7008512 | 0.89 | MMP9 (0.61) | MMP9MMP13MMP1ADAM17LMNA | |
| SCHEMBL7010946 | 0.84 | MMP13 (0.59) | MMP9MMP13MMP1ADAM17NUDT14 | |
| SCHEMBL7006037 | 0.81 | MMP9 (0.82) | MMP9MMP13MMP1ADAM17LMNA | |
| SCHEMBL7143527 | 0.76 | MMP9 (0.77) | MMP9MMP13MMP1ADAM17LMNA | |
| SCHEMBL6290652 | 0.76 | MMP1 (0.57) | MMP9MMP13MMP1ADAM17LMNA | |
| Potassium Ion SCHEMBL7011984 | 0.74 | MMP9 (0.57) | MMP9MMP13MMP1ADAM17MMP2 | |
| SCHEMBL7006608 | 0.72 | MMP9 (0.82) | MMP9MMP13MMP1ADAM17MMP2 | |
| SCHEMBL7012919 | 0.71 | MMP9 (0.76) | MMP9MMP13MMP1ADAM17LMNA | |
| SCHEMBL7164348 | 0.70 | MMP1 (0.43) | MMP9MMP13MMP1ADAM17NUDT14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1021413-B1 | THE PREPARATION AND USE OF ORTHO-SULFONAMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS | WYETH CORP (US) | 2003-06-11 | — | — | EP | disclosed |
| US-6498167-B2 | NITROGEN CONTAINING BICYCLIC HETEROAROMATIC COMPOUND CONTAINING SULFONAMIDE AND HYDROXYAMIDE GROUPS, USEFUL IN TREATMENT OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, BONE DISEASE AND HIV INFECTIONS | AMERICAN CYANAMID COMPANY | 2002-12-24 | — | — | US | disclosed |
| US-20010025047-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | WYETH HOLDINGS CORPORATION | 2001-09-27 | — | — | US | disclosed |
| US-6228869-B1 | ANTITUMOR, ANTIMETASTASIS, ANTIARTHRITIC, AND WOUND HEALING AGENTS; QUINOLINE AND ISOQUINOLINE DERIVATIVES | AMERICAN CYANAMID COMPANY | 2001-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025047-A1 | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors | MSR1, TIMP3, TGFBR2 | MMP9 21/4885MMP13 36/4885MMP1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.